These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
684 related articles for article (PubMed ID: 12520089)
1. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Siegmund D; Hadwiger P; Pfizenmaier K; Vornlocher HP; Wajant H Mol Med; 2002 Nov; 8(11):725-32. PubMed ID: 12520089 [TBL] [Abstract][Full Text] [Related]
2. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771 [TBL] [Abstract][Full Text] [Related]
4. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Grotzer MA; Eggert A; Zuzak TJ; Janss AJ; Marwaha S; Wiewrodt BR; Ikegaki N; Brodeur GM; Phillips PC Oncogene; 2000 Sep; 19(40):4604-10. PubMed ID: 11030149 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763 [TBL] [Abstract][Full Text] [Related]
6. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP Blood; 2002 Mar; 99(6):2162-71. PubMed ID: 11877293 [TBL] [Abstract][Full Text] [Related]
7. Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP. Zeise E; Weichenthal M; Schwarz T; Kulms D J Invest Dermatol; 2004 Oct; 123(4):746-54. PubMed ID: 15373780 [TBL] [Abstract][Full Text] [Related]
8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
10. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389 [TBL] [Abstract][Full Text] [Related]
11. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
12. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204 [TBL] [Abstract][Full Text] [Related]
13. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. Kim Y; Suh N; Sporn M; Reed JC J Biol Chem; 2002 Jun; 277(25):22320-9. PubMed ID: 11940602 [TBL] [Abstract][Full Text] [Related]
14. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915 [TBL] [Abstract][Full Text] [Related]
15. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636 [TBL] [Abstract][Full Text] [Related]
16. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Kelly MM; Hoel BD; Voelkel-Johnson C Cancer Biol Ther; 2002; 1(5):520-7. PubMed ID: 12496481 [TBL] [Abstract][Full Text] [Related]
17. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Ricci MS; Jin Z; Dews M; Yu D; Thomas-Tikhonenko A; Dicker DT; El-Deiry WS Mol Cell Biol; 2004 Oct; 24(19):8541-55. PubMed ID: 15367674 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538 [TBL] [Abstract][Full Text] [Related]
19. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911 [TBL] [Abstract][Full Text] [Related]
20. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Kim JH; Ajaz M; Lokshin A; Lee YJ Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]